Literature DB >> 24900407

Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer.

Fouad H Darras1, Beata Kling1, Jörg Heilmann1, Michael Decker1.   

Abstract

Tri- and tetracyclic nitrogen-bridgehead compounds were designed and synthesized to yield micromolar cholinesterase (ChE) inhibitors. Structure-activity relationships identified potent compounds with butyrylcholinesterase selectivity. These compounds were selected as starting points for the design and synthesis of carbamate-based (pseudo)irreversible inhibitors. Compounds with superior inhibitory activity and selectivity were obtained and kinetically characterized also with regard to the velocity of enzyme carbamoylation. Structural elements were identified and introduced that additionally showed neuroprotective properties on a hippocampal neuronal cell line (HT-22) after glutamate-induced intracellular reactive oxygen species generation. We have identified potent and selective pseudoirreversible butyrylcholinesterase inhibitors that release reversible inhibitors with neuroprotective properties after carbamate transfer to the active site of cholinesterases.

Entities:  

Keywords:  Alzheimer's disease; butyrylcholinesterase; carbamates; neuroprotection

Year:  2012        PMID: 24900407      PMCID: PMC4025739          DOI: 10.1021/ml3001825

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  26 in total

Review 1.  Oxytosis: A novel form of programmed cell death.

Authors:  S Tan; D Schubert; P Maher
Journal:  Curr Top Med Chem       Date:  2001-12       Impact factor: 3.295

2.  Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.

Authors:  Michael Decker
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

3.  Role of oxidative stress on beta-amyloid neurotoxicity elicited during impairment of energy metabolism in the hippocampus: protection by antioxidants.

Authors:  Teresa Montiel; Ricardo Quiroz-Baez; Lourdes Massieu; Clorinda Arias
Journal:  Exp Neurol       Date:  2006-04-19       Impact factor: 5.330

4.  Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells.

Authors:  S Tan; M Wood; P Maher
Journal:  J Neurochem       Date:  1998-07       Impact factor: 5.372

Review 5.  Alzheimer's disease.

Authors:  Clive Ballard; Serge Gauthier; Anne Corbett; Carol Brayne; Dag Aarsland; Emma Jones
Journal:  Lancet       Date:  2011-03-01       Impact factor: 79.321

6.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

Authors:  Nigel H Greig; Tadanobu Utsuki; Donald K Ingram; Yue Wang; Giancarlo Pepeu; Carla Scali; Qian-Sheng Yu; Jacek Mamczarz; Harold W Holloway; Tony Giordano; DeMao Chen; Katsutoshi Furukawa; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

7.  Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.

Authors:  Maria Laura Bolognesi; Manuela Bartolini; Andrea Cavalli; Vincenza Andrisano; Michela Rosini; Anna Minarini; Carlo Melchiorre
Journal:  J Med Chem       Date:  2004-11-18       Impact factor: 7.446

Review 8.  Cholinergic function and Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Int J Geriatr Psychiatry       Date:  2003-09       Impact factor: 3.485

9.  Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity.

Authors:  M Weinstock; E Groner
Journal:  Chem Biol Interact       Date:  2008-04-08       Impact factor: 5.192

10.  Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.

Authors:  Ciaran G Carolan; Gerald P Dillon; Denise Khan; Sheila A Ryder; Joanne M Gaynor; Sean Reidy; Juan F Marquez; Mike Jones; Valerie Holland; John F Gilmer
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

View more
  7 in total

1.  Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model.

Authors:  Philipp Spatz; Thomas Zimmermann; Sophie Steinmüller; Julian Hofmann; Tangui Maurice; Michael Decker
Journal:  RSC Med Chem       Date:  2022-06-20

2.  Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.

Authors:  Fouad H Darras; Steffen Pockes; Guozheng Huang; Sarah Wehle; Andrea Strasser; Hans-Joachim Wittmann; Martin Nimczick; Christoph A Sotriffer; Michael Decker
Journal:  ACS Chem Neurosci       Date:  2014-01-14       Impact factor: 4.418

3.  Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.

Authors:  Suresh K Bowroju; Narsimha R Penthala; Naga Rajiv Lakkaniga; Meenakshisundaram Balasubramaniam; Srinivas Ayyadevara; Robert J Shmookler Reis; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2021-07-14       Impact factor: 3.461

Review 4.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

Authors:  Natalia Guzior; Anna Wieckowska; Dawid Panek; Barbara Malawska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

5.  Experimental and theoretical investigations into the stability of cyclic aminals.

Authors:  Edgar Sawatzky; Antonios Drakopoulos; Martin Rölz; Christoph Sotriffer; Bernd Engels; Michael Decker
Journal:  Beilstein J Org Chem       Date:  2016-10-31       Impact factor: 2.883

6.  New 1,2,3-Triazole-genipin Analogues and Their Anti-Alzheimer's Activity.

Authors:  Patamawadee Silalai; Suwichada Jaipea; Jiraporn Tocharus; Anan Athipornchai; Apichart Suksamrarn; Rungnapha Saeeng
Journal:  ACS Omega       Date:  2022-07-06

7.  Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.

Authors:  Christian Gentzsch; Matthias Hoffmann; Yasuhiro Ohshima; Naoko Nose; Xinyu Chen; Takahiro Higuchi; Michael Decker
Journal:  ChemMedChem       Date:  2021-03-01       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.